Who was studied?
BALB/c mice bearing subcutaneous and intraperitoneal CT26.WT tumors.
What does the publication report?
The triplet reduced growth versus control and checkpoint blockade alone, prolonged survival in specified comparisons and altered circulating CD4+ T cells and granulocytic suppressor cells.
Safety findings
Animal research does not establish human safety.
How should we interpret it?
Preprint evidence. The authors, model and findings overlap substantially with the later Diseases & Research report; these should not be treated as independent replication.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Study of effect of PRaG therapy in colon cancer transplanted tumor mouse model
Related publications from the same research program
- The Anti-tumor Effect and Immunological Cell Changes of PRaG Therapy in Colon Cancer Peritoneal Metastasis of Mice
- Impact of PRaG Therapy on Peripheral Immune Cells of Subcutaneous Tumor Peritoneal Metastasis Model of Colon Cancer
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.